SIGA (SIGA) 10-Q 4 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Oct. 20, 2021
Document Information [Line Items]
Entity Central Index Key	0001010086
Entity Registrant Name	Siga Technologies INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	0-23047
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3864870
Entity Address, Address Line One	31 East 62nd Street
Entity Address, Postal Zip Code	10065
Entity Address, City or Town	New York
Entity Address, State or Province	NY
City Area Code	212
Local Phone Number	672-9100
Title of 12(b) Security	common stock, $.0001 par value
Trading Symbol	SIGA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		74,116,295

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 92,819,425	$ 117,890,240
Accounts receivable	3,822,824	3,340,263
Inventory	29,673,044	20,265,519
Prepaid expenses and other current assets	2,622,254	2,112,069
Total current assets	128,937,547	143,608,091
Property, plant and equipment, net	2,468,463	2,103,990
Deferred income taxes, net	2,952,286	2,544,053
Goodwill	898,334	898,334
Other assets	306,722	676,923
Total assets	135,563,352	149,831,391
Current liabilities
Accounts payable	9,962,965	1,278,217
Accrued expenses and other current liabilities	8,979,128	9,205,293
Total current liabilities	18,942,093	10,483,510
Warrant liability	6,344,663	6,639,211
Other liabilities	3,720,734	2,915,401
Total liabilities	29,007,490	20,038,122
Commitments and contingencies
Stockholders’ equity
Common stock ($.0001 par value, 600,000,000 shares authorized, 74,306,785 and 77,195,704, issued and outstanding at September 30, 2021 and December 31, 2020, respectively)	7,431	7,720
Additional paid-in capital	225,761,819	224,978,430
Accumulated deficit	(119,213,388)	(95,192,881)
Total stockholders’ equity	106,555,862	129,793,269
Total liabilities and stockholders’ equity	$ 135,563,352	$ 149,831,391

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	74,306,785	77,195,704
Common stock, shares outstanding (in shares)	74,306,785	77,195,704

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Total revenues	$ 4,846,172	$ 44,261,407	$ 18,313,206	$ 87,229,949
Operating expenses
Cost of sales and supportive services	83,276	5,559,215	1,330,114	10,465,078
Selling, general and administrative	4,305,644	3,566,258	13,577,887	10,613,267
Research and development	3,235,145	2,073,613	7,801,901	7,933,404
Patent expenses	165,996	164,102	535,497	520,902
Total operating expenses	7,790,061	11,363,188	23,245,399	29,532,651
Operating (loss)/income	(2,943,889)	32,898,219	(4,932,193)	57,697,298
(Loss)/gain from change in fair value of warrant liability	(1,066,522)	(1,274,156)	294,548	(2,909,808)
Loss on extinguishment of Term Loan	0	0	0	(4,981,461)
Interest expense	0	0	0	(3,016,817)
Other income, net	26,252	24,932	76,055	469,226
(Loss)/income before income taxes	(3,984,159)	31,648,995	(4,561,590)	47,258,438
Benefit/(provision) for income taxes	870,801	(7,461,038)	805,328	(11,077,854)
Net and comprehensive (loss)/income	$ (3,113,358)	$ 24,187,957	$ (3,756,262)	$ 36,180,584
Basic (loss)/income per share (in dollars per share)	$ (0.04)	$ 0.31	$ (0.05)	$ 0.45
Diluted (loss)/income per share (in dollars per share)	$ (0.04)	$ 0.31	$ (0.05)	$ 0.45
Weighted average shares outstanding: basic (in shares)	74,840,846	78,080,461	75,822,713	79,880,493
Weighted average shares outstanding: diluted (in shares)	74,840,846	78,168,070	76,634,963	80,051,778
Product Sales and Supportive Services [Member]
Revenues
Total revenues	$ 2,346,110	$ 41,810,192	$ 12,793,615	$ 80,547,651
Research and Development [Member]
Revenues
Total revenues	$ 2,500,062	$ 2,451,215	$ 5,519,591	$ 6,682,298

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net (loss)/income	$ (3,756,262)	$ 36,180,584
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and other amortization	393,667	397,136
(Gain)/loss on change in fair value of warrant liability	(294,548)	2,909,808
Stock-based compensation	957,320	963,372
Loss on inventory, net	548,551	0
Deferred income taxes, net	(408,233)	7,666,891
Loss on extinguishment of Term Loan	0	4,981,461
Non-cash interest expense	0	887,132
Changes in assets and liabilities:
Accounts receivable	(482,561)	(36,230,712)
Inventory	(9,956,076)	1,507,995
Prepaid expenses and other assets	(139,984)	1,494,821
Accounts payable, accrued expenses and other liabilities	8,223,757	474,736
Deferred revenue	306,443	4,339,626
Net cash (used in)/provided by operating activities	(4,607,926)	25,572,850
Cash flows from investing activities:
Capital expenditures	(24,424)	(15,501)
Net cash used in investing activities	(24,424)	(15,501)
Cash flows from financing activities:
Payment of employee tax obligations for common stock tendered	(173,918)	(184,009)
Repurchase of common stock	(20,264,547)	(21,783,289)
Repayment of Term Loan	0	(85,913,459)
Net cash used in financing activities	(20,438,465)	(107,880,757)
Net decrease in cash, cash equivalents and restricted cash	(25,070,815)	(82,323,408)
Cash, cash equivalents and restricted cash at the beginning of period	117,890,240	160,986,934
Cash and cash equivalents at end of period	$ 92,819,425	$ 78,663,526

Note 1 - Condensed Consolidated

Note 1 - Condensed Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Condensed Consolidated Financial Statements The financial statements of SIGA Technologies, Inc. (“we,” “our,” “us,” “SIGA” or the “Company”) are presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10 December 31, 2020 2020 10 March 4, 2021 ( "2020 10 not 2020 10 2020 not three nine September 30, 2021 not

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” September 30, 2021 Note 3 six three one September 30, 2021 not twelve five Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may September 30, 2021 nine September 30, 2021 Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any). Recent Accounting Pronouncements In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, first 2021 no

Note 3 - Procurement Contracts

Note 3 - Procurement Contracts and Research Agreements	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Procurement Contract and Research Agreements [Text Block]	3. 19C On September 10, 2018, September 30, 2021 "19C five $239.7 September 7, 2021 may ten 19C The base period of performance specifies potential payments of approximately $51.7 million for the following activities: payments of approximately $11.1 million for the delivery of approximately 35,700 courses of oral TPOXX® to the Strategic Stockpile; payments of $8.0 million for the manufacture of 20,000 courses of final drug product of IV TPOXX® ("IV FDP"), of which $3.2 million of payments are related to the manufacture of bulk drug substance ("IV BDS") to be used in the manufacture of IV FDP; payments of approximately $32.0 million to fund advanced development of IV TPOXX®; and payments of approximately $0.6 million for supportive procurement activities. As of September 30, 2021 September 30, 2021 December 31, 2020 The options that have been exercised to date provide for payments up to approximately $239.7 million. There are exercised options for the following activities: payments up to $11.2 million for the procurement of raw materials to be used in the manufacture of at least 363,070 courses of oral TPOXX®; payments up to $213.9 million for the delivery of up to 726,140 courses of oral TPOXX®; and payments of up to $14.6 million for funding of post-marketing activities for oral TPOXX®. As of September 30, 2021 2020 October 20, 2021, $33 Unexercised options specify potential payments up to approximately $311.1 million in total (if all such options are exercised). There are options for the following activities: payments of up to $225.1 million for the delivery of oral TPOXX® to the Strategic Stockpile; payments of up to $76.8 million for the manufacture of courses of IV FDP, of which up to $30.7 million of payments would be paid upon the manufacture of IV BDS to be used in the manufacture of IV FDP; payments of up to approximately $3.6 million to fund post-marketing activities for IV TPOXX®; and payments of up to approximately $5.6 million for supportive procurement activities. The options related to IV TPOXX® are divided into two may none 19C three three not 64,000 Revenues in connection with the 19C 19C three September 30, 2021 2020 nine September 30, 2021 2020 three nine September 30, 2021 three nine September 30, 2020 International Procurement Contracts On January 13, 2021, five March 31, 2023; March 31, 2023 September 30, 2021, first six 2021. On April 3, 2020, four second 2020, third 2021, The PHAC and CDND contract awards were both coordinated between SIGA and Meridian under the international promotion agreement (as amended, the "International Promotion Agreement") that was entered into by the parties on June 3, 2019. Under the terms of the International Promotion Agreement, Meridian was granted exclusive rights to market, advertise, promote, offer for sale, or sell oral TPOXX® in a field of use specified in the International Promotion Agreement in all geographic regions except for the United States (the “Territory”), and Meridian has agreed not The fee Meridian retains pursuant to the International Promotion Agreement is a specified percentage of the collected proceeds of sales of oral TPOXX® net of certain expenses, for years in which customer invoiced amounts net of such expenses are less than or equal to a specified threshold, and a higher specified percentage of such collected net proceeds for years in which such net invoiced amounts exceed the specified threshold. Revenue in connection with international procurement contracts for the delivery of product are recognized at a point in time. During the three nine September 30, 2021 Research Agreements and Grants The Company has an R&D program for IV TPOXX®. This program is funded by the 19C February 2024. September 30, 2021 three September 30, 2021 2020 nine September 30, 2021 2020 In July 2019, May 2020, April 2021, April 30, 2024. three September 30, 2021 2020 nine September 30, 2021 2020 On May 13, 2011, "2011 no The 2011 September 30, 2021 The 2011 December 2024. Remaining performance obligations under the 2011 three September 30, 2021 2020 nine September 30, 2021 2020 Contracts and grants include, among other things, options that may may not may not

Note 4 - Inventory

Note 4 - Inventory	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	4. Inventory Inventory includes costs related to the manufacture of TPOXX®. Inventory consisted of the following: As of September 30, 2021 December 31, 2020 Raw materials $ 14,908 $ 2,628,153 Work in-process 28,010,781 15,415,425 Finished goods 1,647,355 2,221,941 Inventory $ 29,673,044 $ 20,265,519 For the nine September 30, 2021,

Note 5 - Property, Plant and Eq

Note 5 - Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property, Plant and Equipment Property, plant and equipment consisted of the following: As of September 30, 2021 December 31, 2020 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 484,866 532,125 Furniture and fixtures 377,859 377,859 Operating lease right-of-use assets 3,678,647 2,944,932 6,961,400 6,274,944 Less - accumulated depreciation and amortization (4,492,937 ) (4,170,954 ) Property, plant and equipment, net $ 2,468,463 $ 2,103,990 Depreciation and amortization expense on property, plant, and equipment was $0.4 million and $0.4 million for the nine September 30, 2021 2020

Note 6 - Accrued Expenses and O

Note 6 - Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accrued Expenses and Other Liabilities [Text Block]	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: As of September 30, 2021 December 31, 2020 Deferred revenue $ 3,587,390 $ 3,280,947 Compensation 2,420,266 2,933,738 Research and development vendor costs 585,854 327,606 Professional fees 585,019 251,824 Lease liability, current portion 496,683 449,940 Inventory 462,390 150,349 Other 416,966 486,158 Vacation 376,303 405,176 Income tax payable 48,257 919,555 Accrued expenses and other current liabilities $ 8,979,128 $ 9,205,293

Note 7 - Financial Instruments

Note 7 - Financial Instruments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Financial Instruments Disclosure [Text Block]	7. Financial Instruments 2016 On September 2, 2016, Note 8 8 ten September 30, 2021 The Company accounts for the Warrant in accordance with the authoritative guidance, which requires that free-standing derivative financial instruments with certain anti-dilution and cash settlement features be classified as assets or liabilities at the time of the transaction and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. The Company classified the Warrant as a liability and reports the change in fair value in the statement of operations. As of September 30, 2021 no As of December 31, 2020, 0.46%; no

Note 8 - Debt

Note 8 - Debt	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. On March 13, 2020, nine September 30, 2020 On September 2, 2016, November 16, 2016 The Term Loan had a maturity date on the earliest to occur of (i) the four

Note 9 - Fair Value of Financia

Note 9 - Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	9. Fair Value of Financial Instruments The carrying value of cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximates fair value due to the relatively short maturity of these instruments. Common stock warrants, which are classified as a liability, are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 • Level 2 not • Level 3 third The Company uses model-derived valuations where certain inputs are unobservable to third 3. Note 7 September 30, 2021 There were no nine September 30, 2021 September 30, 2021 December 31, 2020 1 2 September 30, 2021 The following table presents changes in the liability-classified warrant measured at fair value using Level 3 Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2020 $ 6,639,211 Decrease in fair value of warrant liability (294,548 ) Exercise of warrants — Warrant liability at September 30, 2021 $ 6,344,663

Note 10 - Per Share Data

Note 10 - Per Share Data	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	10. Per Share Data The Company computes, presents and discloses earnings per share in accordance with the authoritative guidance, which specifies the computation, presentation and disclosure requirements for earnings per share of entities with publicly held common stock or potential common stock. The objective of basic EPS is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The following is a reconciliation of the basic and diluted loss per share computation: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net (loss)/income for basic earnings per share $ (3,113,358 ) $ 24,187,957 $ (3,756,262 ) $ 36,180,584 Less: Change in fair value of warrants — — 294,548 — Net (loss)/income, adjusted for change in fair value of warrants for diluted earnings per share $ (3,113,358 ) $ 24,187,957 $ (4,050,810 ) $ 36,180,584 Weighted-average shares 74,840,846 78,080,461 75,822,713 79,880,493 Effect of potential common shares — 87,609 812,250 171,285 Weighted-average shares: diluted 74,840,846 78,168,070 76,634,963 80,051,778 (Loss)/income per share: basic $ (0.04 ) $ 0.31 $ (0.05 ) $ 0.45 (Loss)/income per share: diluted $ (0.04 ) $ 0.31 $ (0.05 ) $ 0.45 For the three nine September 30, 2020, not three nine September 30, 2020 three nine September 30, 2020, For the three nine September 30, 2021 Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 Warrants 1,047,296 — Stock options 150,000 153,055 Restricted stock units 204,591 181,730

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Commitments and Contingencies From time to time, we may not Purchase Commitments In the course of our business, the Company regularly enters into agreements with third not ds. As of September 30, 2021 , the Company had approximat

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions Board of Directors and Outside Counsel A former member of the Company’s Board of Directors who did not 2021 not three September 30, 2021. three September 30, 2020 nine September 30, 2021 2020, September 30, 2021. Real Estate Leases On May 26, 2017, ten 31 62 nd first sixty-three first six first sixty-fourth first second five three nine September 30, 2021

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes The Company’s provision for income taxes consists of federal and state taxes, as applicable, in amounts necessary to align the Company’s year-to-date tax provision with the effective rate that it expects to achieve for the full year. Each quarter the Company updates its estimate of the annual effective tax rate and records cumulative adjustments as necessary. For the three September 30, 2021 2020 For the nine September 30, 2021 2020 The effective tax rate for the three September 30, 2021 three September 30, 2020 three September 30, 2021 162 The effective tax rate for the nine September 30, 2021 nine September 30, 2020 nine September 30, 2021 162

Note 14 - Equity

Note 14 - Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	14. The tables below present changes in stockholders' equity for the three nine September 30, 2021 2020 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2021 75,389,417 $ 7,539 $ 225,678,876 $ (108,965,453 ) $ — $ 116,720,962 Net loss — — (3,113,358 ) — (3,113,358 ) Repurchase of common stock (1,110,763 ) (111 ) — (7,134,577 ) — (7,134,688 ) Payment of common stock tendered for employee stock-based compensation tax obligations (25,203 ) (2 ) (160,554 ) — — (160,556 ) Issuance of common stock upon vesting of RSUs 53,334 5 (5 ) — — — Stock-based compensation — — 243,502 — — 243,502 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2020 77,195,704 $ 7,720 $ 224,978,430 $ (95,192,881 ) $ — $ 129,793,269 Net loss — — — (3,756,262 ) — (3,756,262 ) Repurchase of common stock (3,024,690 ) (302 ) — (20,264,245 ) — (20,264,547 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,105 ) (3 ) (173,915 ) — — (173,918 ) Issuance of common stock upon vesting of RSUs 162,876 16 (16 ) — — — Stock-based compensation — — 957,320 — — 957,320 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Net income — — — 24,187,957 — 24,187,957 Repurchase of common stock (886,472 ) (89 ) — (5,567,032 ) — (5,567,121 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,143 ) (3 ) (174,260 ) — — (174,263 ) Issuance of common stock upon exercise of stock options 11,822 1 (1 ) — — — Issuance of common stock upon vesting of RSUs 53,334 6 (6 ) — — — Stock-based compensation — — 380,823 — — 380,823 Balances at September 30, 2020 77,770,284 $ 7,777 $ 221,587,384 $ (108,634,747 ) $ — $ 112,960,414 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2019 81,269,868 $ 8,127 $ 220,808,037 $ (123,032,408 ) $ — $ 97,783,756 Net income — — — 36,180,584 — 36,180,584 Repurchase of common stock (3,660,247 ) (366 ) — (21,782,923 ) — (21,783,289 ) Payment of common stock tendered for employee stock-based compensation tax obligations (29,035 ) (3 ) (184,006 ) — — (184,009 ) Issuance of common stock upon exercise of stock options 11,822 1 (1 ) — — — Issuance of common stock upon vesting of RSUs 177,876 18 (18 ) — — — Stock-based compensation — — 963,372 — — 963,372 Balances at September 30, 2020 77,770,284 $ 7,777 $ 221,587,384 $ (108,634,747 ) $ — $ 112,960,414 On March 5, 2020, may December 31, 2021. may may 10b5 1 1934, three nine September 30, 2021 September 30, 2021 On August 2, 2021, may December 31, 2023. March 2020 may may 10b5 1 September 30, 2021 no

Note 15 - Leases

Note 15 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	15. The Company leases its Corvallis, Oregon, facilities and office space under an operating lease, which was signed on November 3, 2017 January 1, 2018. December 31, 2019 two one two three second 2019, first December 31, 2021. second 2021, second December 31, 2024. second second 2021. On May 26, 2017 ten no Operating lease costs totaled $0.1 million and $0.2 million for the three September 30, 2021 2020 nine September 30, 2021 2020 three September 30, 2021 2020 nine September 30, 2021 2020 September 30, 2021 Future cash flows under operating leases as of September 30, 2021 2021 $ 150,774 2022 627,731 2023 669,048 2024 678,627 2025 406,994 Thereafter 575,887 Total undiscounted cash flows under leases 3,109,061 Less: Imputed interest (341,124 ) Present value of lease liabilities $ 2,767,937 As of September 30, 2021

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition All of the Company’s revenue is derived from long-term contracts that span multiple years. The Company accounts for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers 606” September 30, 2021 Note 3 six three one September 30, 2021 not twelve five Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Contract modifications may not The Company’s performance obligations are satisfied over time as work progresses or at a point in time. All of the Company’s revenue related to current research and development performance obligations is recognized over time, because the customer simultaneously receives and consumes the benefits provided by the services as the Company performs these services. The Company recognizes revenue related to these services based on the progress toward complete satisfaction of the performance obligation and measures this progress under an input method, which is based on the Company’s cost incurred relative to total estimated costs. Under this method, progress is measured based on the cost of resources consumed (i.e., cost of third third Contract Balances The timing of revenue recognition, billings and cash collections may September 30, 2021 nine September 30, 2021
Stockholders' Equity, Policy [Policy Text Block]	Repurchase of shares When shares recognized as equity are repurchased, the amount of the consideration paid, which includes directly attributable costs, is recognized as a deduction from equity. The excess of the purchase price above par value of repurchased shares that are retired is presented as an increase to accumulated deficit (or a reduction of retained earnings, if any).
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In December 2019, No. 2019 12, Simplifying the Accounting for Income Taxes December 15, 2020, first 2021 no

Note 4 - Inventory (Tables)

Note 4 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of September 30, 2021 December 31, 2020 Raw materials $ 14,908 $ 2,628,153 Work in-process 28,010,781 15,415,425 Finished goods 1,647,355 2,221,941 Inventory $ 29,673,044 $ 20,265,519

Note 5 - Property, Plant and _2

Note 5 - Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of September 30, 2021 December 31, 2020 Leasehold improvements $ 2,420,028 $ 2,420,028 Computer equipment 484,866 532,125 Furniture and fixtures 377,859 377,859 Operating lease right-of-use assets 3,678,647 2,944,932 6,961,400 6,274,944 Less - accumulated depreciation and amortization (4,492,937 ) (4,170,954 ) Property, plant and equipment, net $ 2,468,463 $ 2,103,990

Note 6 - Accrued Expenses and_2

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Accrued Expenses and Other Current Liabilities [Table Text Block]	As of September 30, 2021 December 31, 2020 Deferred revenue $ 3,587,390 $ 3,280,947 Compensation 2,420,266 2,933,738 Research and development vendor costs 585,854 327,606 Professional fees 585,019 251,824 Lease liability, current portion 496,683 449,940 Inventory 462,390 150,349 Other 416,966 486,158 Vacation 376,303 405,176 Income tax payable 48,257 919,555 Accrued expenses and other current liabilities $ 8,979,128 $ 9,205,293

Note 9 - Fair Value of Financ_2

Note 9 - Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Fair Value Measurements of Level 3 liability-classified warrant Warrant liability at December 31, 2020 $ 6,639,211 Decrease in fair value of warrant liability (294,548 ) Exercise of warrants — Warrant liability at September 30, 2021 $ 6,344,663

Note 10 - Per Share Data (Table

Note 10 - Per Share Data (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net (loss)/income for basic earnings per share $ (3,113,358 ) $ 24,187,957 $ (3,756,262 ) $ 36,180,584 Less: Change in fair value of warrants — — 294,548 — Net (loss)/income, adjusted for change in fair value of warrants for diluted earnings per share $ (3,113,358 ) $ 24,187,957 $ (4,050,810 ) $ 36,180,584 Weighted-average shares 74,840,846 78,080,461 75,822,713 79,880,493 Effect of potential common shares — 87,609 812,250 171,285 Weighted-average shares: diluted 74,840,846 78,168,070 76,634,963 80,051,778 (Loss)/income per share: basic $ (0.04 ) $ 0.31 $ (0.05 ) $ 0.45 (Loss)/income per share: diluted $ (0.04 ) $ 0.31 $ (0.05 ) $ 0.45
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2021 Warrants 1,047,296 — Stock options 150,000 153,055 Restricted stock units 204,591 181,730

Note 14 - Equity (Tables)

Note 14 - Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders Equity [Table Text Block]	Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2021 75,389,417 $ 7,539 $ 225,678,876 $ (108,965,453 ) $ — $ 116,720,962 Net loss — — (3,113,358 ) — (3,113,358 ) Repurchase of common stock (1,110,763 ) (111 ) — (7,134,577 ) — (7,134,688 ) Payment of common stock tendered for employee stock-based compensation tax obligations (25,203 ) (2 ) (160,554 ) — — (160,556 ) Issuance of common stock upon vesting of RSUs 53,334 5 (5 ) — — — Stock-based compensation — — 243,502 — — 243,502 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2020 77,195,704 $ 7,720 $ 224,978,430 $ (95,192,881 ) $ — $ 129,793,269 Net loss — — — (3,756,262 ) — (3,756,262 ) Repurchase of common stock (3,024,690 ) (302 ) — (20,264,245 ) — (20,264,547 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,105 ) (3 ) (173,915 ) — — (173,918 ) Issuance of common stock upon vesting of RSUs 162,876 16 (16 ) — — — Stock-based compensation — — 957,320 — — 957,320 Balances at September 30, 2021 74,306,785 $ 7,431 $ 225,761,819 $ (119,213,388 ) $ — $ 106,555,862 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at June 30, 2020 78,618,743 $ 7,862 $ 221,380,828 $ (127,255,672 ) $ — $ 94,133,018 Net income — — — 24,187,957 — 24,187,957 Repurchase of common stock (886,472 ) (89 ) — (5,567,032 ) — (5,567,121 ) Payment of common stock tendered for employee stock-based compensation tax obligations (27,143 ) (3 ) (174,260 ) — — (174,263 ) Issuance of common stock upon exercise of stock options 11,822 1 (1 ) — — — Issuance of common stock upon vesting of RSUs 53,334 6 (6 ) — — — Stock-based compensation — — 380,823 — — 380,823 Balances at September 30, 2020 77,770,284 $ 7,777 $ 221,587,384 $ (108,634,747 ) $ — $ 112,960,414 Common Stock Additional Paid-in Accumulated Other Comprehensive Total Stockholders' Shares Amount Capital Deficit Income Equity Balances at December 31, 2019 81,269,868 $ 8,127 $ 220,808,037 $ (123,032,408 ) $ — $ 97,783,756 Net income — — — 36,180,584 — 36,180,584 Repurchase of common stock (3,660,247 ) (366 ) — (21,782,923 ) — (21,783,289 ) Payment of common stock tendered for employee stock-based compensation tax obligations (29,035 ) (3 ) (184,006 ) — — (184,009 ) Issuance of common stock upon exercise of stock options 11,822 1 (1 ) — — — Issuance of common stock upon vesting of RSUs 177,876 18 (18 ) — — — Stock-based compensation — — 963,372 — — 963,372 Balances at September 30, 2020 77,770,284 $ 7,777 $ 221,587,384 $ (108,634,747 ) $ — $ 112,960,414

Note 15 - Leases (Tables)

Note 15 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 $ 150,774 2022 627,731 2023 669,048 2024 678,627 2025 406,994 Thereafter 575,887 Total undiscounted cash flows under leases 3,109,061 Less: Imputed interest (341,124 ) Present value of lease liabilities $ 2,767,937

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies 1 (Details Textual) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 177.2
Contract with Customer, Asset, after Allowance for Credit Loss, Total	2.6
Contract with Customer, Liability, Revenue Recognized	$ 0.1

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies 2 (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 177.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-10-01
Revenue, Remaining Performance Obligation, Amount	$ 112.6
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Month)	12 months

Note 3 - Procurement Contract_2

Note 3 - Procurement Contracts and Research Agreements (Details Textual) $ in Thousands	Sep. 07, 2021USD ($)	Jan. 13, 2021USD ($)	Apr. 03, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Apr. 30, 2021USD ($)	Dec. 31, 2020USD ($)	May 31, 2020USD ($)	Jul. 31, 2019USD ($)	Sep. 10, 2018USD ($)	May 13, 2011USD ($)
Contract with Customer, Liability, Revenue Recognized							$ 100
The 19C BARDA Contract [Member]
Number of Courses to Be Delivered														1,488,000
Number of Courses Stored As Vendor Managed Inventory														212,000
Government Contract, Value of Award				$ 602,500			602,500		$ 602,500
Government Contract, Base Period, Value of Award for Delivery and Support Activities				51,700			$ 51,700		51,700					$ 51,700
Base Period of Performance (Year)							5 years
Government Contract, Value, Payments Remaining Related to Exercised Options							$ 239,700
Government Contract, Value, Payments Currently Specified as Unexercised Options							$ 311,100
Government Contract, Option Exercised, Value of Consideration	$ 112,600
Base Period of Performance, Exercise of Options, Term (Year)							10 years
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Delivery of Courses														$ 11,100
Government Contract, Base Period, Number of Deliveries														35,700
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses														$ 8,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Advanced Development														32,000
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Supportive Procurement Activities														$ 600
Proceeds from Delivery of Courses							$ 11,100
Number of Courses Delivered							35,700
Government Contract, Value of Unexercised Options, Supportive Procurement Activities				5,600			$ 5,600		5,600
The 19C BARDA Contract [Member] | Transferred over Time [Member]
Contract with Customer, Liability, Revenue Recognized				1,100	$ 1,800		2,800	$ 5,200
The 19C BARDA Contract [Member] | Transferred at Point in Time [Member]
Contract with Customer, Liability, Revenue Recognized				0	41,400		0	77,700
The 19C BARDA Contract [Member] | IV TPOXX [Member]
Government Contract, Base Period, Number of Courses Manufactured														20,000
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses				225,100			225,100		225,100
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities				$ 3,600			$ 3,600		$ 3,600
Number of Manufacturing Steps				2			2		2
The 19C BARDA Contract [Member] | IV BDS [Member]
Government Contract, Base Period, Value of Award for Delivery and Support Activities, Manufacture of Courses														$ 3,200
Proceeds from the Manufacture of Courses							$ 3,200
Proceeds from Other Base Period Activities							11,800
Contract with Customer, Liability, Total				$ 3,200			3,200		$ 3,200		$ 3,200
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses				$ 30,700			$ 30,700		$ 30,700
Government Contract, Number of Options for Manufacture of Product				3			3		3
Government Contract, Courses Manufactured Upon Exercise of Options				64,000			64,000		64,000
The 19C BARDA Contract [Member] | Oral TPOXX [Member]
Number of Courses to Be Delivered				726,140			726,140		726,140
Proceeds from Delivery of Courses							$ 7,100
Government Contract, Value, Payments Related to Exercised Options, Procurement of Raw Materials				$ 11,200			$ 11,200		$ 11,200
Number of Courses to be Manufactured				363,070			363,070		363,070
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses				$ 213,900			$ 213,900		$ 213,900
Government Contract, Value, Payments Related to Exercised Options, Funding of Post-Marketing Activities				14,600			14,600		14,600
Proceeds for the Procurement of Raw Materials							112,500
The 19C BARDA Contract [Member] | IV FDP [Member]
Government Contract, Value, Payments Related to Exercised Options, Delivery of Courses				76,800			76,800		76,800
Government Contract, Value, Payments Currently Specified as Unexercised Options, Manufacture of Courses				$ 76,800			$ 76,800		$ 76,800
Government Contract, Number of Options for Manufacture of Product				3			3		3
Government Contract, Courses Manufactured Upon Exercise of Options				64,000			64,000		64,000
Meridian Contract [Member] | Oral TPOXX [Member]
Government Contract, Value of Award		$ 33,000
Contract with Customer, Liability, Revenue Recognized							$ 10,300
Government Contract, Term (Year)		5 years
Government Contract, Firm Commitment not Subject to Option Exercise		$ 17,000
Canadian Contract [Member] | Meridian Medical Technologies [Member]
Contract with Customer, Liability, Revenue Recognized				$ 2,300			12,700
Government Contract, Term (Year)			4 years
Other Commitment, Total			$ 14,000
Canadian Contract [Member] | Meridian Medical Technologies [Member] | Purchases from Q2 of 2020 [Member]
Contract with Customer, Liability, Revenue Recognized						$ 2,300
Canadian Contract [Member] | Meridian Medical Technologies [Member] | Purchases from Q3 of 2021 [Member]
Contract with Customer, Liability, Revenue Recognized				2,300
The IV Formulation R & D Contract with BARDA [Member]
Contract with Customer, Liability, Revenue Recognized				100	400		600	1,100
Government Contract, Future Aggregate Research and Development Funding				800			800		$ 800
The PEP Label Expansion R & D Contract with the Department of Defense [Member]
Contract with Customer, Liability, Revenue Recognized				1,300	200		2,000	300
Grants Receivable										$ 26,000		$ 26,000	$ 19,500
Government Contract, Initial Award												$ 23,000	$ 12,400
The 2011 BARDA Contract [Member]
Number of Courses to Be Delivered															1,700,000
Government Contract, Value of Award															$ 508,400
Number of Courses Delivered									1,700,000
Contract with Customer, Liability, Revenue Recognized				100	$ 100		100	$ 200
Number of Additional Courses to be Delivered at No Additional Cost															300,000
Proceeds from the Manufacture and Delivery of Courses									$ 459,800
Proceeds from Reimbursements in Connection with Development and Supportive Activities									45,800
Amount Eligible to be Received for Reimbursements of Development and Supportive Activities				$ 2,800			$ 2,800		$ 2,800

Note 4 - Inventory (Details Tex

Note 4 - Inventory (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Inventory Write-down, Net of Credits	$ 548,551	$ 0
Inventory Write-down	$ 900,000

Note 4 - Inventory - Inventory

Note 4 - Inventory - Inventory (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Raw materials	$ 14,908	$ 2,628,153
Work in-process	28,010,781	15,415,425
Finished goods	1,647,355	2,221,941
Inventory	$ 29,673,044	$ 20,265,519

Note 5 - Property, Plant and _3

Note 5 - Property, Plant and Equipment (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Depreciation, Depletion and Amortization, Total	$ 393,667	$ 397,136

Note 5 - Property, Plant and _4

Note 5 - Property, Plant and Equipment - Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 6,961,400	$ 6,274,944
Operating lease right-of-use assets	3,678,647	2,944,932
Less - accumulated depreciation and amortization	(4,492,937)	(4,170,954)
Property, plant and equipment, net	2,468,463	2,103,990
Leasehold Improvements [Member]
Property, plant and equipment, gross	2,420,028	2,420,028
Computer Equipment [Member]
Property, plant and equipment, gross	484,866	532,125
Furniture and Fixtures [Member]
Property, plant and equipment, gross	$ 377,859	$ 377,859

Note 6 - Accrued Expenses and_3

Note 6 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Deferred revenue	$ 3,587,390	$ 3,280,947
Compensation	2,420,266	2,933,738
Research and development vendor costs	585,854	327,606
Professional fees	585,019	251,824
Inventory	462,390	150,349
Other	416,966	486,158
Vacation	376,303	405,176
Income tax payable	48,257	919,555
Accrued expenses and other current liabilities	8,979,128	9,205,293
Accrued Expenses and Other Current Liabilities [Member]
Lease liability, current portion	$ 496,683	$ 449,940

Note 7 - Financial Instruments

Note 7 - Financial Instruments (Details Textual) $ / shares in Units, shares in Millions	Sep. 30, 2021USD ($)shares	Dec. 31, 2020USD ($)	Sep. 02, 2016USD ($)$ / sharesshares
Warrants and Rights Outstanding | $	$ 6,344,663	$ 6,639,211
The 2016 Warrant [Member]
Class of Warrant or Right Outstanding, Common Stock Value Used to Determine Number of Shares Called | $			$ 4,000,000
Class of Warrant or Right Outstanding, Common Stock Price Per Share Used to Determine Number of Shares Called (in dollars per share) | $ / shares			$ 2.29
Warrants and Rights Outstanding, Term (Year)			10 years
Class of Warrant or Right, Subscription Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares	1		2.7
Warrants and Rights Outstanding | $	$ 6,300,000
Warrants and Rights Outstanding, Measurement Input	6,600,000
The 2016 Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0096	0.0046
The 2016 Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
The 2016 Warrant [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	4.9	5.7
The 2016 Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.50	0.80

Note 8 - Debt (Details Textual)

Note 8 - Debt (Details Textual) - USD ($)	Mar. 13, 2020	Nov. 16, 2016	Sep. 02, 2016	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Oct. 01, 2020	Sep. 30, 2020
Repayments of Long-term Debt, Principal						$ 0		$ 85,913,459
Gain (Loss) on Extinguishment of Debt, Total				$ 0	$ 0	$ 0		$ (4,981,461)
Loan Agreement [Member] | Term Loan [Member] | OCM Strategic Credit SIGTEC Holdings, LLC [Member]
Repayments of Long-term Debt Including Interest	$ 87,200,000
Repayments of Long-term Debt, Principal	80,000,000
Repayments of Long-term Debt, Repayment Fee	4,000,000
Interest Paid, Including Capitalized Interest, Operating and Investing Activities, Total	1,200,000
Repayments of Long-term Debt, Prepayment Premium	$ 1,900,000
Gain (Loss) on Extinguishment of Debt, Total							$ (5,000,000)
Proceeds from Issuance of Debt		$ 80,000,000
Debt Instrument, Term (Year)			4 years

Note 9 - Fair Value of Financ_3

Note 9 - Fair Value of Financial Instruments (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Warrants and Rights Outstanding	$ 6,344,663	$ 6,639,211
Fair Value, Inputs, Level 1 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	100,000	$ 100,000
Fair Value, Inputs, Level 2 [Member]
Cash and Cash Equivalents, Fair Value Disclosure	0
The 2016 Warrant [Member]
Warrants and Rights Outstanding	$ 6,300,000

Note 9 - Fair Value of Financ_4

Note 9 - Fair Value of Financial Instruments - Changes in the Liability-classified Warrant Measured at Fair Value (Details)	9 Months Ended
	Sep. 30, 2021USD ($)
Warrant liability	$ 6,639,211
Decrease in fair value of warrant liability	(294,548)
Exercise of warrants	0
Warrant liability	$ 6,344,663

Note 10 - Per Share Data (Detai

Note 10 - Per Share Data (Details Textual) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,205,829	1,146,898

Note 10 - Per Share Data - Reco

Note 10 - Per Share Data - Reconciliation of the Basic and Diluted Loss Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net (loss)/income	$ (3,113,358)	$ 24,187,957	$ (3,756,262)	$ 36,180,584
Less: Change in fair value of warrants	0	0	294,548	0
Net (loss)/income, adjusted for change in fair value of warrants for diluted earnings per share	$ (3,113,358)	$ 24,187,957	$ (4,050,810)	$ 36,180,584
Weighted average shares outstanding: basic (in shares)	74,840,846	78,080,461	75,822,713	79,880,493
Effect of potential common shares (in shares)	0	87,609	812,250	171,285
Weighted-average shares: diluted (in shares)	74,840,846	78,168,070	76,634,963	80,051,778
Basic (loss)/income per share (in dollars per share)	$ (0.04)	$ 0.31	$ (0.05)	$ 0.45
Diluted (loss)/income per share (in dollars per share)	$ (0.04)	$ 0.31	$ (0.05)	$ 0.45

Note 10 - Per Share Data - Anti

Note 10 - Per Share Data - Antidilutive Securities Excluded from Computation (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive securities (in shares)		1,205,829		1,146,898
Warrant [Member]
Antidilutive securities (in shares)	1,047,296		0
Share-based Payment Arrangement, Option [Member]
Antidilutive securities (in shares)	150,000		153,055
Restricted Stock Units (Stock Settled) [Member]
Antidilutive securities (in shares)	204,591		181,730

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) $ in Millions	Sep. 30, 2021USD ($)
Purchase Commitment, Remaining Minimum Amount Committed	$ 4.9

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual)	May 26, 2017USD ($)ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Outside Counsel [Member]
Legal Fees		$ 0	$ 100,000	$ 100,000	$ 400,000
Accounts Payable, Related Parties		0		0
MacAndrews and Forbes Incorporated [Member] | The New HQ Lease [Member]
Lessee, Operating Lease, Term of Contract (Year)	10 years
Area of Real Estate Property (Square Foot) | ft²	3,200
Monthly Rent During Initial Period	$ 25,333
Monthly Rent, Initial Period (Month)	63 months
Monthly Rent After Initial Period	$ 29,333
Monthly Facility Fee, Second Year	$ 3,333
Monthly Facility Fee, Yearly Rate Increase After Second Year	5.00%
Monthly Facility Fee, Final Year	$ 4,925
Operating Lease, Expense		$ 100,000		$ 200,000

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income (Loss) Attributable to Parent, before Tax, Total	$ (4,000,000)	$ 31,600,000	$ (4,600,000)	$ 47,300,000
Income Tax Expense (Benefit), Total	$ (870,801)	$ 7,461,038	$ (805,328)	$ 11,077,854
Effective Income Tax Rate Reconciliation, Percent, Total	21.90%	23.60%	17.70%	23.40%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%		21.00%
Effective Income Tax Rate Reconciliation, Expiration of Stock Options, Amount			$ 200,000

Note 14 - Equity (Details Textu

Note 14 - Equity (Details Textual) - USD ($) shares in Thousands	2 Months Ended	3 Months Ended		9 Months Ended		19 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Aug. 02, 2021	Mar. 05, 2020
Stock Repurchase Program, Authorized Amount								$ 50,000,000
Stock Repurchased During Period, Shares (in shares)		1,100		3,000
Stock Repurchased During Period, Value		$ 7,134,688	$ 5,567,121	$ 20,264,547	$ 21,783,289	$ 48,800,000
New Repurchase Authorization [Member]
Stock Repurchase Program, Authorized Amount							$ 50,000,000
Stock Repurchased During Period, Shares (in shares)	0

Note 14 - Equity - Changes in S

Note 14 - Equity - Changes in Stockholders' Equity (Details) - USD ($)	3 Months Ended		9 Months Ended		19 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021
Balances	$ 116,720,962	$ 94,133,018	$ 129,793,269	$ 97,783,756
Net income (loss)	$ (3,113,358)	24,187,957	$ (3,756,262)	36,180,584
Repurchase of common stock (in shares)	(1,100,000)		(3,000,000)
Repurchase of common stock	$ (7,134,688)	(5,567,121)	$ (20,264,547)	(21,783,289)	$ (48,800,000)
Payment of common stock tendered for employee stock-based compensation tax obligations	(160,556)	(174,263)	(173,918)	(184,009)
Issuance of common stock upon vesting of RSUs	0	0	0	0
Stock-based compensation	243,502	380,823	957,320	963,372
Issuance of common stock upon exercise of stock options		0		0
Balances	$ 106,555,862	$ 112,960,414	$ 106,555,862	$ 112,960,414	$ 106,555,862
Common Stock [Member]
Balances (in shares)	75,389,417	78,618,743	77,195,704	81,269,868
Balances	$ 7,539	$ 7,862	$ 7,720	$ 8,127
Net income (loss)	$ 0	$ 0	$ 0	$ 0
Repurchase of common stock (in shares)	(1,110,763)	(886,472)	(3,024,690)	(3,660,247)
Repurchase of common stock	$ (111)	$ (89)	$ (302)	$ (366)
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)	(25,203)	(27,143)	(27,105)	(29,035)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ (2)	$ (3)	$ (3)	$ (3)
Issuance of common stock upon vesting of RSUs (in shares)	53,334	53,334	162,876	177,876
Issuance of common stock upon vesting of RSUs	$ 5	$ 6	$ 16	$ 18
Stock-based compensation	$ 0	$ 0	$ 0	$ 0
Issuance of common stock upon exercise of stock options (in shares)		11,822		11,822
Issuance of common stock upon exercise of stock options		$ 1		$ 1
Balances (in shares)	74,306,785	77,770,284	74,306,785	77,770,284	74,306,785
Balances	$ 7,431	$ 7,777	$ 7,431	$ 7,777	$ 7,431
Additional Paid-in Capital [Member]
Balances	225,678,876	221,380,828	224,978,430	220,808,037
Net income (loss)	0	0	0	0
Repurchase of common stock	0	0	0	0
Payment of common stock tendered for employee stock-based compensation tax obligations	(160,554)	(174,260)	(173,915)	(184,006)
Issuance of common stock upon vesting of RSUs	(5)	(6)	(16)	(18)
Stock-based compensation	243,502	380,823	957,320	963,372
Issuance of common stock upon exercise of stock options		(1)		(1)
Balances	225,761,819	221,587,384	225,761,819	221,587,384	225,761,819
Retained Earnings [Member]
Balances	(108,965,453)	(127,255,672)	(95,192,881)	(123,032,408)
Net income (loss)	(3,113,358)	24,187,957	(3,756,262)	36,180,584
Repurchase of common stock	(7,134,577)	(5,567,032)	(20,264,245)	(21,782,923)
Payment of common stock tendered for employee stock-based compensation tax obligations	0	0	0	0
Issuance of common stock upon vesting of RSUs	0	0	0	0
Stock-based compensation	0	0	0	0
Issuance of common stock upon exercise of stock options		0		0
Balances	(119,213,388)	(108,634,747)	(119,213,388)	(108,634,747)	(119,213,388)
AOCI Attributable to Parent [Member]
Balances	0	0	0	0
Net income (loss)	0	0	0	0
Repurchase of common stock	0	0	0	0
Payment of common stock tendered for employee stock-based compensation tax obligations	0	0	0	0
Issuance of common stock upon vesting of RSUs	0	0	0	0
Stock-based compensation	0	0	0	0
Issuance of common stock upon exercise of stock options		0		0
Balances	$ 0	$ 0	$ 0	$ 0	$ 0

Note 15 - Leases (Details Textu

Note 15 - Leases (Details Textual)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2019	May 26, 2017ft²
Operating Lease, Cost	$ 100,000		$ 200,000	$ 400,000	$ 500,000
Operating Lease, Payments	$ 100,000		$ 100,000	$ 400,000	$ 400,000
Operating Lease, Weighted Average Remaining Lease Term (Year)	4 years 9 months 14 days			4 years 9 months 14 days
Operating Lease, Weighted Average Discount Rate, Percent	4.53%			4.53%
Operating Lease, Liability, Total	$ 2,767,937			$ 2,767,937
Other Liabilities [Member]
Operating Lease, Liability, Total	$ 2,300,000			$ 2,300,000
Facilities and Office Space in Corvallis Oregon [Member]
Lessee, Operating Lease, First Renewal Term (Year)						2 years
Lessee, Operating Lease, Second Renewal Term (Year)						3 years
Increase (Decrease) in Operating Lease Liability		$ 700,000
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 700,000
The New HQ Lease [Member] | MacAndrews and Forbes Incorporated [Member]
Lessee, Operating Lease, Term of Contract (Year)							10 years
Area of Real Estate Property (Square Foot) | ft²							3,200

Note 15 - Leases - Future Undis

Note 15 - Leases - Future Undiscounted Cash Flows Under Operating Leases (Details)	Sep. 30, 2021USD ($)
2021	$ 150,774
2022	627,731
2023	669,048
2024	678,627
2025	406,994
Thereafter	575,887
Total undiscounted cash flows under leases	3,109,061
Less: Imputed interest	(341,124)
Present value of lease liabilities	$ 2,767,937